Hepatocellular Carcinoma (HCC)Phase 2CONV3RSIONNCT07483359
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
A Phase 2 study testing HAIC + Tislelizumab +lenvatinib in people with Hepatocellular Carcinoma (HCC) and Portal Vein Tumor Thrombus, run by First Hospital of China Medical University at 1 site in China.
Trial summary
Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenvatinib, and Tislelizumab-designed to… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus
- What is being tested?
- HAIC + Tislelizumab +lenvatinib
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteChina
- Study dates
- 20 May 2026to May 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must meet all of the following inclusion criteria to be enrolled in this trial:
- Voluntarily sign the written informed consent form.
- Age 18 to 80 years (inclusive), male or female.
- Histologically or cytologically confirmed Hepatocellular Carcinoma (HCC) according to the "Clinical Practice Guideline for Primary Liver Cancer (2024 Edition)," and evaluated by a Multi-Disciplinary Team (MDT) as initially unresectable.
- No prior systemic anti-tumor therapy (including targeted therapy, immunotherapy, and systemic chemotherapy).
- Barcelona Clinic Liver Cancer (BCLC) stage C and China Liver Cancer (CNLC) stage IIIa, complicated with imaging-confirmed Vp3 portal vein tumor thrombus (PVTT, defined as tumor thrombus invading the first-order branches of the portal vein but not the main trunk).
Show all 17Show fewer
- At least one measurable target lesion according to RECIST v1.1 criteria.
- Expected survival time of ≥ 3 months.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
- Child-Pugh liver function class A or B (score ≤ 7).
- Adequate major organ function, meeting the following baseline laboratory criteria:
- Hematology: Hemoglobin ≥ 90 g/L; Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L; Platelet count ≥ 75 x 10^9/L.
- Biochemistry: Albumin ≥ 28 g/L; Total Bilirubin ≤ 3 x Upper Limit of Normal (ULN); AST and ALT ≤ 5 x ULN; Alkaline Phosphatase (ALP) ≤ 5 x ULN; Serum Creatinine ≤ 1.5 x ULN.
- Coagulation: INR or Prothrombin Time (PT) ≤ 1.5 x ULN; Activated Partial Thromboplastin Time (APTT) ≤ 1.5 x ULN.
- Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment, must not be breastfeeding, and must agree to use highly effective contraception during the study treatment and for at least 6 months after the last dose.
- Good compliance and willingness to cooperate with all study-related follow-up procedures.
- Assessed by the MDT as "Potentially Resectable" according to the "Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)". This is defined as participants who are temporarily unsuitable for upfront surgical resection due to oncological factors (e.g., Vp3 PVTT indicating a high risk of early post-operative recurrence) or technical factors (e.g., massive tumor size leading to insufficient future liver remnant [FLR]), but who are expected to convert to an R0 resection and achieve significant clinical benefit following downstaging with the combination of FOLFOX-HAIC and systemic therapy.
Who cannot join
- Participants who meet any of the following criteria will be excluded from the study:
- History of other active malignancies within 5 years (except for adequately treated basal cell carcinoma of the skin or papillary thyroid cancer).
- Evidence of extrahepatic metastasis confirmed by chest, abdomen, and pelvis CT and/or MRI scans.
- Presence of clinically significant ascites.
- History of hepatic encephalopathy.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on chest CT scan at screening.
Show all 14Show fewer
- Severe infection within 4 weeks prior to enrollment, including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia.
- History of hypertensive crisis; or major cardiovascular disease within 3 months prior to starting study treatment (e.g., New York Heart Association [NYHA] Class II or worse heart failure, myocardial infarction, cerebrovascular accident, unstable arrhythmia, or unstable angina).
- Inadequately controlled arterial hypertension, defined as systolic blood pressure (BP) ≥ 150 mmHg and/or diastolic BP > 100 mmHg (based on an average of ≥ 3 BP readings obtained from ≥ 2 measurements). Achieving these parameters through the use of antihypertensive therapy is permitted.
- Severe vascular disease within 6 months (e.g., aortic aneurysm requiring surgical repair or peripheral arterial thrombosis); or a current or recent history of active autoimmune disease or immunodeficiency (including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis).
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the investigational drugs, may affect the interpretation of the results, or may place the patient at high risk for treatment-related complications.
- Use of systemic immunosuppressive medications within 2 weeks prior to the first dose of study treatment, or the expected need for long-term systemic immunosuppressive therapy during the study. Exceptions permitting the use of corticosteroids include: (1) prophylactic use to prevent allergic reactions to imaging contrast media (e.g., short-term dexamethasone); (2) topical, ophthalmic, intra-articular, otic, or inhaled corticosteroids with minimal systemic absorption; (3) physiological replacement doses of systemic corticosteroids (defined as ≤ 10 mg/day of prednisone or an equivalent corticosteroid).
- Evidence of bleeding diathesis or severe coagulopathy.
- Patients preparing to undergo, or who have previously received, a solid organ or allogeneic bone marrow transplant.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, 110000
Haibo Shao, MD, PhD, +8613840150051, hbshao@cmu.edu.cn
Jiaxi Liu, MD, +8618940279150, dmuvictor@163.com
About this study
Official title: Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib and Tislelizumab for Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus: A Prospective, Multicenter, Single-arm Study
Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenvatinib, and Tislelizumab-designed to induce significant regression of both the tumor burden and the PVTT. The primary objective is to determine the Technical Resectability Rate (TRR), assessing the potential for this triple-combination therapy to downstage initially unresectable disease to a state suitable for curative-intent R0 surgical resection.
Read the detailed description
This prospective, multicenter, single-arm clinical trial evaluates the efficacy and safety of a triple-combination conversion therapy for patients with initially unresectable hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT). The study aims to enroll 38 participants to assess the technical resectability rate (TRR) as the primary endpoint. Participants undergo a 21-day treatment cycle consisting regimens of intravenous Tislelizumab, FOLFOX-based hepatic arterial infusion chemotherapy (HAIC), while receiving daily oral Lenvatinib. This combination is designed to leverage the synergistic effects of high-concentration local chemotherapy and systemic targeted-immunotherapy to induce significant regression of both the tumor burden and the PVTT.
The clinical pathway centers on regular response evaluations conducted every two cycles using multimodal radiological imaging. During these intervals, a dual-evaluation mechanism is employed: a Multi-Disciplinary Team (MDT) reviews the clinical and radiological data to guide real-time surgical decision-making, while a Blinded Independent Review Committee (IRC) independently evaluates the scans to formally determine the primary endpoint of technical resectability. This assessment focuses on anatomical feasibility for R0 resection, the adequacy of the future liver remnant, and the successful downstaging of the PVTT. Patients meeting the clinical conversion criteria proceed to curative-intent surgical intervention, followed by a pathological complete response (pCR) assessment.
For participants who remain technically unresectable but continue to demonstrate clinical benefit, the HAIC intervention is limited to a maximum of six cycles. In these cases, systemic targeted and immunotherapy are maintained until disease progression, intolerable toxicity, or a maximum treatment duration of 24 months. The study officially concludes upon the earliest occurrence of either: the completion of the protocol-defined one-year overall survival follow-up for the final enrolled participant (including the achievement of the pre-specified data cutoff), or the point at which all surviving participants have experienced definitive disease progression or death and further data collection is no longer required.
- Being tested
- HAIC + Tislelizumab +lenvatinib
- Keywords
- Conversion Therapy, Hepatic Arterial Infusion Chemotherapy, Tislelizumab, Lenvatinib, Vp3 Portal Vein Tumor Thrombus
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HAIC + Tislelizumab +lenvatinibCombination product
Tislelizumab: 200 mg administered intravenously each 21-day cycle.
FOLFOX-HAIC: Administered every 21 days for up to a maximum of 6 cycles. The regimen consists of Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-Fluorouracil 2500 mg/m² given as a continuous hepatic arterial infusion over 46-48 hours.
Lenvatinib: Administered orally once daily on a continuous basis. Dosing is weight-adjusted: 12 mg/day for patients weighing ≥60 kg, and 8 mg/day for patients weighing <60 kg.
| Study group | Role | What they receive |
|---|---|---|
| HAIC plus lenvatinib and tislelizumab | Experimental | Participants receive a 21-day cycle consisting of intravenous immunotherapy (Tislelizumab), local hepatic arterial infusion chemotherapy (FOLFOX-HAIC), and daily oral targeted therapy (Lenvatinib). Receives: Combination Product: HAIC + Tislelizumab +lenvatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Technical Resectability Rate (TRR)
The percentage of participants whose disease converts from initially unresectable to technically resectable, as evaluated by a Blinded Independent Review Committee (IRC) based on multimodal radiological imaging. The criteria for successful conversion include the anatomical feasibility of achieving an R0 resection, the adequacy of the future liver remnant (FLR), and the successful downstaging of the Vp3 portal vein tumor thrombus (PVTT).
Measured: Up to approximately 2 years.
Secondary outcomes (11)
1-Year Overall Survival (OS) Rate
The percentage of participants who remain alive at 12 months from the date of the first dose of study treatment.
Measured: 12 months from the first dose of study treatment.
Progression-Free Survival (PFS) per RECIST v1.1
Time from the first dose of study treatment to the first documented objective disease progression, as assessed by the IRC using RECIST v1.1 criteria, or death from any cause, whichever occurs first.
Measured: Up to approximately 2 years.
Progression-Free Survival (PFS) per mRECIST
Time from the first dose of study treatment to the first documented objective disease progression, as assessed by the IRC using modified RECIST (mRECIST) criteria for hepatocellular carcinoma, or death from any cause, whichever occurs first.
Measured: Up to approximately 2 years.
Time to Progression (TTP) per RECIST v1.1
Time from the first dose of study treatment to the first documented objective disease progression, as assessed by the IRC using RECIST v1.1 criteria.
Measured: Up to approximately 2 years.
Time to Progression (TTP) per mRECIST
Time from the first dose of study treatment to the first documented objective disease progression, as assessed by the IRC using modified RECIST (mRECIST) criteria for hepatocellular carcinoma.
Measured: Up to approximately 2 years.
Objective Response Rate (ORR) per RECIST v1.1
The percentage of participants who achieve a confirmed Complete Response (CR) or Partial Response (PR), as assessed by the Blinded Independent Review Committee (IRC) using RECIST v1.1 criteria. To be considered a confirmed response, the CR or PR must be maintained and verified by a subsequent radiological assessment conducted at least 4 weeks (28 days) after the initial response criteria are met.
Measured: Up to approximately 2 years.
Objective Response Rate (ORR) per mRECIST
The percentage of participants who achieve a confirmed Complete Response (CR) or Partial Response (PR), as assessed by the Blinded Independent Review Committee (IRC) using modified RECIST (mRECIST) criteria, which specifically evaluates viable (arterially enhancing) tumor tissue. To be considered a confirmed response, the CR or PR must be maintained and verified by a subsequent radiological assessment conducted at least 4 weeks (28 days) after the initial response criteria are met.
Measured: Up to approximately 2 years.
Portal Vein Tumor Thrombus (PVTT) Response Rate
The percentage of participants in the Intent-to-Treat (ITT) population who achieve an objective response in the portal vein tumor thrombus. This is defined as either a PVTT Complete Response (PVTT-CR; complete disappearance of the thrombus with vascular recanalization) or a PVTT Partial Response (PVTT-PR; a downgrade in the Vp classification, such as from Vp3 to Vp2 or Vp1), as evaluated by the IRC using multimodal radiological imaging.
Measured: Up to approximately 2 years.
Actual Resection Rate (ARR)
The percentage of participants in the Intent-to-Treat (ITT) population who actually undergo and successfully complete a curative-intent R0 surgical resection following the study treatment.
Measured: Up to approximately 2 years.
Pathological Complete Response (pCR) Rate
The percentage of participants undergoing surgical resection who achieve a pathological complete response (pCR). This is defined as the complete absence of any residual viable tumor cells in both the primary hepatic lesion and the resected portal vein tumor thrombus (PVTT), as confirmed by post-operative histopathological examination of the resected specimens.
Measured: Up to approximately 2 years.
Incidence and Severity of Adverse Events (AEs)
The number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) will be recorded. The severity of all AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Special attention will be given to tracking adverse events of special interest (AESIs), including HAIC-related complications and immune-related adverse events (irAEs).
Measured: Through 30 days after the last dose of study treatment (up to 2 years).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start20 May 2026
- Primary completionJun 2027 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Hospital of China Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Yanbian University
- Responsible party
- Principal investigator, Kai Li, First Hospital of China Medical University
- Investigators
- Kai Li, MD, PhD, Principal investigator, First Hospital of China Medical UniversityHaibo Shao, MD, PhD, Principal investigator, First Hospital of China Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07483359
- Sponsor's protocol ID
- 2026-CONV3RSION-01
- Acronym
- CONV3RSION
- Status last verified
- May 2026
- First submitted
- 16 Mar 2026
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib and Tislelizumab for Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus: A Prospective, Multicenter, Single-arm Study
- ClinicalTrials.gov ID
- NCT07483359
- Acronym / sponsor ID
- CONV3RSION / 2026-CONV3RSION-01
- Keywords
- Conversion Therapy, Hepatic Arterial Infusion Chemotherapy, Tislelizumab, Lenvatinib, Vp3 Portal Vein Tumor Thrombus
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- First Hospital of China Medical UniversityUniversity, hospital or other
- Collaborators
- Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Yanbian University
- Study start
- 20 May 2026 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenvatinib, and Tislelizumab-designed to induce significant regression of both the tumor burden and the PVTT. The primary objective is to determine the Technical Resectability Rate (TRR), assessing the potential for this triple-combination therapy to downstage initially unresectable disease to a state suitable for curative-intent R0 surgical resection.
Detailed description
This prospective, multicenter, single-arm clinical trial evaluates the efficacy and safety of a triple-combination conversion therapy for patients with initially unresectable hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT). The study aims to enroll 38 participants to assess the technical resectability rate (TRR) as the primary endpoint. Participants undergo a 21-day treatment cycle consisting regimens of intravenous Tislelizumab, FOLFOX-based hepatic arterial infusion chemotherapy (HAIC), while receiving daily oral Lenvatinib. This combination is designed to leverage the synergistic effects of high-concentration local chemotherapy and systemic targeted-immunotherapy to induce significant regression of both the tumor burden and the PVTT.
The clinical pathway centers on regular response evaluations conducted every two cycles using multimodal radiological imaging. During these intervals, a dual-evaluation mechanism is employed: a Multi-Disciplinary Team (MDT) reviews the clinical and radiological data to guide real-time surgical decision-making, while a Blinded Independent Review Committee (IRC) independently evaluates the scans to formally determine the primary endpoint of technical resectability. This assessment focuses on anatomical feasibility for R0 resection, the adequacy of the future liver remnant, and the successful downstaging of the PVTT. Patients meeting the clinical conversion criteria proceed to curative-intent surgical intervention, followed by a pathological complete response (pCR) assessment.
For participants who remain technically unresectable but continue to demonstrate clinical benefit, the HAIC intervention is limited to a maximum of six cycles. In these cases, systemic targeted and immunotherapy are maintained until disease progression, intolerable toxicity, or a maximum treatment duration of 24 months. The study officially concludes upon the earliest occurrence of either: the completion of the protocol-defined one-year overall survival follow-up for the final enrolled participant (including the achievement of the pre-specified data cutoff), or the point at which all surviving participants have experienced definitive disease progression or death and further data collection is no longer required.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HAIC plus lenvatinib and tislelizumab | Experimental | Combination Product: HAIC + Tislelizumab +lenvatinibParticipants receive a 21-day cycle consisting of intravenous immunotherapy (Tislelizumab), local hepatic arterial infusion chemotherapy (FOLFOX-HAIC), and daily oral targeted therapy (Lenvatinib). |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Participants must meet all of the following inclusion criteria to be enrolled in this trial:
- Voluntarily sign the written informed consent form.
- Age 18 to 80 years (inclusive), male or female.
- Histologically or cytologically confirmed Hepatocellular Carcinoma (HCC) according to the "Clinical Practice Guideline for Primary Liver Cancer (2024 Edition)," and evaluated by a Multi-Disciplinary Team (MDT) as initially unresectable.
- No prior systemic anti-tumor therapy (including targeted therapy, immunotherapy, and systemic chemotherapy).
Key exclusion criteria (14 listed)
- History of other active malignancies within 5 years (except for adequately treated basal cell carcinoma of the skin or papillary thyroid cancer).
- Evidence of extrahepatic metastasis confirmed by chest, abdomen, and pelvis CT and/or MRI scans.
- Presence of clinically significant ascites.
- History of hepatic encephalopathy.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on chest CT scan at screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HAIC + Tislelizumab +lenvatinibTislelizumab: 200 mg administered intravenously each 21-day cycle. FOLFOX-HAIC: Administered every 21 days for up to a maximum of 6 cycles. The regimen consists of Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-Fluorouracil 2500 mg/m² given as a continuous hepatic arterial infusion over 46-48 hours. Lenvatinib: Administered orally once daily on a continuous basis. Dosing is weight-adjusted: 12 mg/day for patients weighing ≥60 kg, and 8 mg/day for patients weighing <60 kg. | Combination product | HAIC plus lenvatinib and tislelizumab |
Primary outcome
Technical Resectability Rate (TRR)
Time frame: Up to approximately 2 years.
The percentage of participants whose disease converts from initially unresectable to technically resectable, as evaluated by a Blinded Independent Review Committee (IRC) based on multimodal radiological imaging. The criteria for successful conversion include the anatomical feasibility of achieving an R0 resection, the adequacy of the future liver remnant (FLR), and the successful downstaging of the Vp3 portal vein tumor thrombus (PVTT).
11 secondary outcomes
1-Year Overall Survival (OS) Rate
Time frame: 12 months from the first dose of study treatment.
Progression-Free Survival (PFS) per RECIST v1.1
Time frame: Up to approximately 2 years.
Progression-Free Survival (PFS) per mRECIST
Time frame: Up to approximately 2 years.
Time to Progression (TTP) per RECIST v1.1
Time frame: Up to approximately 2 years.
Time to Progression (TTP) per mRECIST
Time frame: Up to approximately 2 years.
Objective Response Rate (ORR) per RECIST v1.1
Time frame: Up to approximately 2 years.
Objective Response Rate (ORR) per mRECIST
Time frame: Up to approximately 2 years.
Portal Vein Tumor Thrombus (PVTT) Response Rate
Time frame: Up to approximately 2 years.
Actual Resection Rate (ARR)
Time frame: Up to approximately 2 years.
Pathological Complete Response (pCR) Rate
Time frame: Up to approximately 2 years.
Incidence and Severity of Adverse Events (AEs)
Time frame: Through 30 days after the last dose of study treatment (up to 2 years).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Carcinoma (HCC)
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kai Li, MD, PhD principal investigator
First Hospital of China Medical University
Haibo Shao, MD, PhD principal investigator
First Hospital of China Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing HAIC + Tislelizumab +lenvatinib in people with Hepatocellular Carcinoma (HCC) and Portal Vein Tumor Thrombus, run by First Hospital of China Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Haibo Shao, MD, PhD (+8613840150051, hbshao@cmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technical Resectability Rate (TRR) (time frame: Up to approximately 2 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.